{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T09:34:11Z","timestamp":1793007251704,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012182.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000}}],"reference-count":177,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012182.pub3","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:15:52Z","timestamp":1768781752000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cannabis-based medicines for chronic neuropathic pain in adults"],"prefix":"10.1002","volume":"2026","author":[{"given":"G\u00fclay","family":"Ate\u015f","sequence":"additional","affiliation":[{"name":"Institute for Digitalization and General Medicine, Center for Rare Diseases Aachen (ZSEA); Medical Faculty RWTH Aachen University; Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Welsch","sequence":"additional","affiliation":[{"name":"Medical Center Pain Medicine and Mental Health; Saarbr\u00fccken Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Klose","sequence":"additional","affiliation":[{"name":"Internal and Integrative Medicine; Faculty of Medicine, Evang. Kliniken Essen-Mitte, University of Duisburg-Essen; Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor","family":"Phillips","sequence":"additional","affiliation":[{"name":"Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics); University of Oxford, Pain Research Unit, Churchill Hospital; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Lambers","sequence":"additional","affiliation":[{"name":"UVSD SchmerzLOS e.V. - Independent Association of Pain Patients; Neum\u00fcnster Germany"},{"name":"Departement of Health & Social; Hochschule Fresenius gemeinn\u00fctzige Tr\u00e4gergesellschaft mbH - University of Applied Science; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"H\u00e4user","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine and Psychotherapy; Technische Universit\u00e4t M\u00fcnchen; M\u00fcnchen Germany"},{"name":"Medical Center Pain Medicine and Mental Health; Saarbr\u00fccken Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Radbruch","sequence":"additional","affiliation":[{"name":"Palliative Medicine; University Hospital Bonn; Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"10.1002\/14651858.CD012182.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"f2690","DOI":"10.1136\/bmj.f2690","article-title":"Expect analgesic failure; pursue analgesic success","volume":"346","author":"Moore","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1002\/14651858.CD012182.pub3-BIB0002|cit2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012182.pub2","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","author":"M\u00fccke","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Jensen TS Baron R Haanp\u00e4\u00e4 M Kalso E Loeser JD Rice AS A new definition of neuropathic pain Pain 2011 152 10 2204 5 10.1016\/j.pain.2011.06.017","DOI":"10.1016\/j.pain.2011.06.017"},{"issue":"11","key":"10.1002\/14651858.CD012182.pub3-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","article-title":"The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study","volume":"155","author":"Demant","year":"2014","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD012182.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.19","article-title":"Individualized pharmacological treatment of neuropathic pain","volume":"97","author":"Helfert","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD012182.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.neuron.2012.02.008","article-title":"Deconstructing the neuropathic pain phenotype to reveal neural mechanisms","volume":"73","author":"Von Hehn","year":"2012","journal-title":"Neuron"},{"issue":"1","key":"10.1002\/14651858.CD012182.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1474-4422(11)70281-","article-title":"Chronic pain: genes, plasticity, and phenotypes","volume":"11","author":"Baron","year":"2012","journal-title":"Lancet Neurology"},{"issue":"7","key":"10.1002\/14651858.CD012182.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1474-4422(12)70134-5","article-title":"The role of the immune system in the generation of neuropathic pain","volume":"11","author":"Calvo","year":"2012","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","article-title":"Classification Committee of the Neuropathic Pain Special Interest Group (NeuPSIG). The IASP classification of chronic pain for ICD-11: chronic neuropathic pain","volume":"160","author":"Scholz","year":"2019","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"Van Hecke","year":"2014","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD012182.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/papr.12050","article-title":"The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain","volume":"14","author":"Moore","year":"2014","journal-title":"Pain Practice"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1399-6576.2007.01486.x","article-title":"Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey","volume":"52","author":"Gustorff","year":"2008","journal-title":"Acta Anaesthesiologica Scandinavica"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jpain.2005.11.008","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey","volume":"7","author":"Torrance","year":"2006","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2296-9-26","article-title":"Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005","volume":"9","author":"Hall","year":"2008","journal-title":"BMC Family Practice"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000110284","article-title":"Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984","volume":"10","author":"Katusic","year":"1991","journal-title":"Neuroepidemiology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0304-3959(94)90086-8","article-title":"Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion","volume":"56","author":"Rappaport","year":"1994","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pain.2009.08.023","article-title":"Incidence of facial pain in the general population","volume":"147","author":"Koopman","year":"2009","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0019|cit19","volume-title":"Stevens A, Raftery J, Mant J, Simpson S, Editor(s). Health Care Needs Assessment, 3rd Series","author":"McQuay","year":"2007"},{"issue":"3","key":"10.1002\/14651858.CD012182.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jpain.2003.12.004","article-title":"Clinical characteristics and economic costs of patients with painful neuropathic disorders","volume":"5","author":"Berger","year":"2004","journal-title":"Journal of Pain"},{"issue":"1","key":"10.1002\/14651858.CD012182.pub3-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1533-2500.2008.00244.x","article-title":"Clinical and economic characteristics of patients with painful neuropathic disorders in Germany","volume":"9","author":"Berger","year":"2009","journal-title":"Pain Practice"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2377-12-8","article-title":"Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study","volume":"12","author":"Berger","year":"2012","journal-title":"BMC Neurology"},{"issue":"9","key":"10.1002\/14651858.CD012182.pub3-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.vaccine.2005.09.026","article-title":"The burden of herpes zoster: a prospective population based study","volume":"24","author":"Scott","year":"2006","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0024|cit24","first-page":"f7339","article-title":"Drugs for neuropathic pain","volume":"347","author":"Kalso","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"10","key":"10.1002\/14651858.CD012182.pub3-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010902.pub2","article-title":"Oral nonsteroidal anti-inflammatory drugs for neuropathic pain","author":"Moore","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD012182.pub3-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010111","article-title":"Topical capsaicin (low concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD012182.pub3-BIB0027|cit27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010958.pub2","article-title":"Topical lidocaine for neuropathic pain in adults","author":"Derry","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012182.pub3-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007393.pub4","article-title":"Topical capsaicin (high concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012182.pub3-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012182.pub3-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub4","article-title":"Gabapentin for chronic neuropathic pain in adults","author":"Wiffen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD012182.pub3-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub3","article-title":"Amitriptyline for neuropathic pain in adults","author":"Moore","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2377-8-","article-title":"Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012182.pub3-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076.pub2","article-title":"Pregabalin for acute and chronic pain in adults","author":"Moore","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012182.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/j.1532-2149.2013.00341.x","article-title":"Duloxetine use in chronic painful conditions - individual patient data responder analysis","volume":"18","author":"Moore","year":"2014","journal-title":"European Journal of Pain (London, England)"},{"issue":"11","key":"10.1002\/14651858.CD012182.pub3-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010567.pub2","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews","author":"Wiffen","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"104232","DOI":"10.1016\/j.lpm.2024.104232","article-title":"Neuropathic pain: evidence based recommendations","volume":"53","author":"Moisset","year":"2024","journal-title":"La Presse M\u00e9dicale"},{"issue":"7","key":"10.1002\/14651858.CD012182.pub3-BIB0037|cit37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010692.pub3","article-title":"Oxycodone for neuropathic pain in adults","author":"Gaskell","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012182.pub3-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011604.pub2","article-title":"Hydromorphone for neuropathic pain in adults","author":"Stannard","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ejp.1494","article-title":"Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration","volume":"24","author":"Sommer","year":"2020","journal-title":"European Journal of Pain (London, England)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anesthesia"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s42238-022-00142-z","article-title":"Medical cannabis regulation: an overview of models around the world with emphasis on the Brazilian scenario","volume":"4","author":"Souza","year":"2022","journal-title":"Journal of Cannabis Research"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/525S6a","article-title":"Drug development: the treasure chest","volume":"525","author":"Owens","year":"2015","journal-title":"Nature"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroscience.2011.11.020","article-title":"Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence","volume":"204","author":"Hillard","year":"2012","journal-title":"Neuroscience"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1155\/2001\/469629","article-title":"Medicinal use of cannabis: history and current status","volume":"6","author":"Kalant","year":"2001","journal-title":"Pain Research & Management"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2022038592","article-title":"Applications of cannabinoids in neuropathic pain: an updated review","volume":"41","author":"Arthur","year":"2024","journal-title":"Critical Reviews in Therapeutic Drug Carrier Systems"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"104822","DOI":"10.1016\/j.phrs.2020.104822","article-title":"Cannabis sativa: much more beyond \u03949-tetrahydrocannabinol","volume":"157","author":"Alves","year":"2020","journal-title":"Pharmacology Research"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/187152709789824660","article-title":"The endocannabinoid system and pain","volume":"8","author":"Guindon","year":"2009","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0049|cit49","first-page":"123","article-title":"Amygdala activity contributes to the dissociative effect of cannabis on pain perception","volume":"134","author":"Lee","year":"2013","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2174\/1381612820666141027115508","article-title":"Can modulating inflammatory response be a good strategy to treat neuropathic pain?","volume":"21","author":"Zhang","year":"2015","journal-title":"Current Pharmaceutical Design"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/ejp.1297","article-title":"European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management","volume":"22","author":"H\u00e4user","year":"2018","journal-title":"European Journal of Pain (London, England)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/PR9.000000000000076","article-title":"Protocol for the systematic review and meta-analysis of studies in which cannabinoids were tested for antinociceptive effects in animal models of pathological or injury-related persistent pain","volume":"4","author":"Soliman","year":"2019","journal-title":"Pain Reports"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Krcevski-Skvarc N Wells C H\u00e4user W Availability and approval of cannabis-based medicines for chronic pain management and palliative\/supportive care in Europe \u2013 a survey of the status in the chapters of the European Pain Federation European Journal Pain 2018 22 440 54","DOI":"10.1002\/ejp.1147"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"H\u00e4user W Petzke F Fitzcharles MA Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - an overview of systematic reviews European Journal of Pain 2018 22 455 70","DOI":"10.1002\/ejp.1118"},{"issue":"12","key":"10.1002\/14651858.CD012182.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jpain.2015.07.009","article-title":"Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data","volume":"16","author":"Andreae","year":"2015","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/ejp.1946","article-title":"Medicinal cannabis for chronic pain: the Bermuda triangle of low-quality studies, countless meta-analyses and conflicting recommendations","volume":"16","author":"Eisenberg","year":"2022","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/j.pain.0000000000002265","article-title":"International Association for the Study of Pain Presidential Task Force on cannabis and cannabinoid analgesia position statement","volume":"162","author":"IASP Presidential Task Force on cannabis and cannabinoid analgesia","year":"2021","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/j.pain.0000000000001929","article-title":"Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials","volume":"162 (Suppl 1)","author":"Fisher","year":"2021","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"479","DOI":"10.17245\/jdapm.2021.21.6.479","article-title":"Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis","volume":"21","author":"Sainsbury","year":"2021","journal-title":"Journal of Dental Anesthesia and Pain Medicine"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.22267","article-title":"The dilemma of medical marijuana use by rheumatology patients","volume":"66","author":"Fitzcharles","year":"2014","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jrsm.1599","article-title":"Identifying and managing problematic trials: a research integrity assessment tool for randomized controlled trials in evidence synthesis","volume":"14","author":"Weibel","year":"2023","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/bmj.332.7547.969","article-title":"Reporting attrition in randomised controlled trials","volume":"332","author":"Dumville","year":"2006","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0064|cit64","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Chapter 10: Analysing data and undertaking meta-analyses [last updated November 2024]. In: Higgins JP, Thomas J,Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0065|cit65","unstructured":"Cumpston M Lasserson T Flemyng E Page MJ Chapter III: Reporting the review [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0066|cit66","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews Cochrane: London, Version August 2023. Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.pain.2012.05.024","article-title":"Mechanisms of pain in multiple sclerosis: a combined clinical and neurophysiological study","volume":"153","author":"Truini","year":"2012","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","article-title":"Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Koppel","year":"2014","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD012182.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/j.pain.0000000000000311","article-title":"What is the meaning of \"small fiber neuropathy\" in fibromyalgia?","volume":"156","author":"Clauw","year":"2015","journal-title":"Pain"},{"issue":"7","key":"10.1002\/14651858.CD012182.pub3-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011694","article-title":"Cannabinoids for fibromyalgia","author":"Walitt","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00132-004-0645-0","article-title":"How neuropathic is sciatica? The mixed pain concept","volume":"33","author":"Baron","year":"2004","journal-title":"Orthop\u00e4de"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.7326\/M21-4520","article-title":"Cannabis-based products for chronic pain: a systematic review","volume":"175","author":"McDonagh","year":"2022","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1874467212666190215112036","article-title":"New insights in cannabinoid receptor structure and signaling","volume":"12","author":"Ye","year":"2019","journal-title":"Current Molecular Pharmacology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"20,270","DOI":"10.1073\/pnas.0909411106","article-title":"Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo","volume":"106","author":"Long","year":"2009","journal-title":"Proceedings of the National Academy of Science of the United States of America"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0076|cit76","unstructured":"Palliative and Supportive Care Group PaPaS author and referee guidance papas.cochrane.org\/papas-documents (accessed 8 September 2025)"},{"issue":"2","key":"10.1002\/14651858.CD012182.pub3-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0078|cit78","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice E6(R2); November 2016 Available at https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0079|cit79","unstructured":"International Council for Harmonisation Medical Dictionary for Regulatory Activities Version 28.0. 2025 https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/SMQ_intguide_28_0_English.pdf"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0080|cit80","unstructured":"Cochrane Central Register of Controlled Trials (CENTRAL) CENTRAL; 2025, Issue1 https:\/\/www.cochranelibrary.com\/central"},{"issue":"7","key":"10.1002\/14651858.CD012182.pub3-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.jpain.2024.104736","article-title":"Enhancing the trustworthiness of pain research: a call to action","volume":"16","author":"Belton","year":"2024","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0083|cit83","unstructured":"Cochrane database of systematic reviews: editorial policies (last update 09 December 2024) www.cochranelibrary.com\/cdsr\/editorial-policies#problematicstudies (accessed 8 September 2025)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"CD014682","DOI":"10.1002\/14651858.CD014682.pub2","article-title":"Antidepressants for pain management in adults with chronic pain: a network meta-analysis","volume":"5","author":"Birkinshaw","year":"2023","journal-title":"Cochrane Database Systematic Reviews"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"e023600","DOI":"10.1136\/bmjopen-2018-023600","article-title":"Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials","volume":"9","author":"Onakpoya","year":"2019","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","article-title":"NeuPSIG Review Update Study Group. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis","volume":"24","author":"Soliman","year":"2025","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.pain.2004.09.013","article-title":"Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial","volume":"112","author":"Berman","year":"2004","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD012182.pub3-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/npp.2008.120;","article-title":"Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial","volume":"34","author":"Ellis","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bmj.39429.619653.80","article-title":"Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study","volume":"336","author":"Frank","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00415-012-6739-4","article-title":"A double-blind, randomized, placebo-controlled, parallel-group study of THC\/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis","volume":"260","author":"Langford","year":"2013","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0091|cit91","unstructured":"Sativex versus placebo when added to existing treatment for central neuropathic pain in MS https:\/\/clinicaltrials.gov\/search?term=NCT00391079"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0092|cit92","unstructured":"A study of Sativex for pain relief due to diabetic neuropathy clinicaltrials.gov\/ct2\/results?term=NCT00710424+&Search=Search"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0093|cit93","unstructured":"A study to evaluate the effects of cannabis based medicine in patients with pain of neurological origin clinicaltrials.gov\/ct2\/results?cond=&term=NCT01606176&cntry1=&state1=&recrs="},{"key":"10.1002\/14651858.CD012182.pub3-BIB0094|cit94","unstructured":"A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury Clinicaltrials.gov\/Ct2\/Results?term= NCT 01606202&Search=Search"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.pain.2007.08.028","article-title":"Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial","volume":"133","author":"Nurmikko","year":"2007","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0096|cit96","unstructured":"A study of sativex for relief of peripheral neuropathic pain associated with allodynia https:\/\/clinicaltrials.gov\/study\/NCT00711880"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","article-title":"Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis","volume":"65","author":"Rog","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0098|cit98","unstructured":"A study of Sativex in the treatment of central neuropathic pain due to multiple sclerosis https:\/\/clinicaltrials.gov\/study\/NCT01604265"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000481089","article-title":"Dronabinol is a safe long-term treatment option for neuropathic pain patients","volume":"78","author":"Schimrigk","year":"2017","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2337\/dc09-1029","article-title":"Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor","volume":"33","author":"Selvarajah","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/j.1532-2149.2013.00445.x","article-title":"A double-blind, randomized, placebo-controlled, parallel group study of THC\/CBD spray in peripheral neuropathic pain treatment","volume":"18","author":"Serpell","year":"2014","journal-title":"European Journal of Pain (London, England)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0102|cit102","unstructured":"A study of Sativex for pain relief of peripheral neuropathic pain associated with allodynia https:\/\/clinicaltrials.gov\/study\/NCT00710554"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bmj.38149.566979.AE","article-title":"Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial","volume":"329","author":"Svendsen","year":"2004","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.pain.2012.06.024","article-title":"An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain","volume":"153","author":"Toth","year":"2012","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/1389201020666191202111534","article-title":"The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities","volume":"21","author":"Xu","year":"2020","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000542511","article-title":"Efficacy and safety of transdermal medical cannabis (THC: CBD: CBN formula) to treat painful diabetic peripheral neuropathy of lower extremities","volume":"14","author":"Seevathee","year":"2025","journal-title":"Medical Cannabis and Cannabinoids"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"e1556","DOI":"10.1089\/can.2023.0253","article-title":"Topical cannabidiol for established chemotherapy-induced neuropathy: a pilot randomized placebo-controlled trial","volume":"9","author":"D'Andre","year":"2024","journal-title":"Cannabis and Cannabinoid Research"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/cpt.2016","article-title":"Cannabidivarin for HIV-associated neuropathic pain: a randomized, blinded, controlled clinical trial","volume":"109","author":"Eibach","year":"2021","journal-title":"Clinical Pharmacolology & Therapeutics"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/ph16081079","article-title":"Cannabis-based medicine for neuropathic pain and spasticity: a multicenter, randomized, double-blinded, placebo-controlled trial","volume":"16","author":"Hansen","year":"2023","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpainsymman.2013.02.018","article-title":"A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain","volume":"47","author":"Lynch","year":"2014","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ejp.2072","article-title":"Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment","volume":"27","author":"Zubcevic","year":"2023","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0112|cit112","unstructured":"International Committee of Medical Journal Editors Clinical trial registration in recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals; 2018 Available from http:\/\/www.icmje.org\/icmje-recommendations.pdf"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0114|cit114","first-page":"1","article-title":"Regulation (EU) 2017\/745 of the European Parliament and of the Councilof 5 April 2017 on medical devices, amending Directive 2001\/83\/EC, Regulation (EC) No 178\/2002 and Regulation (EC) No 1223\/2009 and repealing Council Directives 90\/385\/EEC and 93\/42\/EEC","volume":"L 117","author":"European Union","year":"2017","journal-title":"Official Journal of the European Union"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0115|cit115","unstructured":"Clinical trial approval in Europe https:\/\/toolbox.eupati.eu\/resources\/clinical-trial-approval-in-europe (accessed 8 September 2025)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.17226\/24625","volume-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","author":"National Academies of Sciences","year":"2017"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0117|cit117","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"CD014915","DOI":"10.1002\/14651858.CD014915.pub2","article-title":"Cannabis-based medicines and medical cannabis for adults with cancer pain","volume":"6","author":"H\u00e4user","year":"2023","journal-title":"Cochrane Database Systematic Reviews"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00482-014-1451-1","article-title":"Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration","volume":"29","author":"Schaefert","year":"2015","journal-title":"Schmerz (Berlin, Germany)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0120|cit120","volume-title":"An Evidence-Based Resource for Pain Relief","author":"McQuay","year":"1998"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0121|cit121","first-page":"15","volume-title":"Systematic Reviews in Pain Research: Methodology Refined","author":"Moore","year":"2008"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0122|cit122","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11136-013-0443-4","article-title":"Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences","volume":"23","author":"Fayers","year":"2014","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0125|cit125","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","article-title":"Meta-analysis in clinical research","volume":"107","author":"L'Abb\u00e9","year":"1987","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0127|cit127","first-page":"557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0128|cit128","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl LA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"E694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/01.wnl.0000253187.66183.9c","article-title":"Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial","volume":"68","author":"Abrams","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1503\/cmaj.110837","article-title":"Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial","volume":"184","author":"Corey-Bloom","year":"2012","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.290.13.1757","article-title":"Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial","volume":"290","author":"Karst","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2044.2004.03674.x","article-title":"Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies","volume":"59","author":"Notcutt","year":"2004","journal-title":"Anaesthesia"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"Arandomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(\u00ae)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/PHM.0b013e3181f1c4ec","article-title":"Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study","volume":"89","author":"Rintala","year":"2010","journal-title":"American Journal of Physical Medicine & Rehabilitation"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/pme.12569","article-title":"Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial","volume":"16","author":"Turcotte","year":"2015","journal-title":"Pain Medicine (Malden, Mass.)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1191\/0269215503cr581oa","article-title":"A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms","volume":"17","author":"Wade","year":"2003","journal-title":"Clinical Rehabilitation"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","article-title":"Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients","volume":"10","author":"Wade","year":"2004","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jpain.2015.03.008","article-title":"Efficacy of inhaled cannabis on painful diabetic neuropathy","volume":"16","author":"Wallace","year":"2015","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jpain.2007.12.010","article-title":"A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain","volume":"9","author":"Wilsey","year":"2008","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","article-title":"Low-dose vaporized cannabis significantly improves neuropathic pain","volume":"14","author":"Wilsey","year":"2013","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00415-006-0218-8","article-title":"Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial","volume":"253","author":"Wissel","year":"2006","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/jnnp-2012-302468","article-title":"Multiple sclerosis and extract of cannabis: results of the MUSEC trial","volume":"83","author":"Zajicek","year":"2012","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1179\/016164109X12590518685660","article-title":"A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis","volume":"32","author":"Collin","year":"2010","journal-title":"Neurology Research"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1007\/s00415-015-7878-1","article-title":"Sativex and clinical\u2013neurophysiological measures of spasticityin progressive multiple sclerosis","volume":"262","author":"Leocani","year":"2015","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/00207454.2018.1481066","article-title":"Sativex\u00ae as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial","volume":"129","author":"Markov\u00e0","year":"2019","journal-title":"International Journal of Neuroscience"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/CORR.0000000000003221","article-title":"Does Cannabis-based Medicine Improve Pain and Sleep Quality in Patients With Traumatic Brachial Plexus Injuries? A Triple-blind, Crossover, Randomized Controlled Trial","volume":"483","author":"Kittithamvongs","year":"2025","journal-title":"Clinical Orthopaedics and Related Research"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0149|cit149","unstructured":"Effects of vaporized marijuana on neuropathic pain https:\/\/clinicaltrials.gov\/study\/NCT01037088"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0150|cit150","unstructured":"Effect of cannabis and endocannabinoids on HIV neuropathic pain https:\/\/clinicaltrials.gov\/study\/NCT03099005"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40263-024-01085-0","article-title":"Oral Delta-9-Tetrahydrocannabinol (THC) Increases Parasympathetic Activity and Supraspinal Conditioned Pain Modulation in Chronic Neuropathic Pain Male Patients: a Crossover, Double-Blind, Placebo-Controlled Trial","volume":"38","author":"Weizman","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0152|cit152","unstructured":"Nabilone for the treatment of phantom limb pain clinicaltrials.gov\/ct2\/show\/NCT00699634?term=NCT00699634&rank=1"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0153|cit153","unstructured":"Efficacy study of nabilone in the treatment of diabetic peripheral neuropathic pain clinicaltrials.gov\/ct2\/show\/NCT01035281?term=NCT01035281&rank=1"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0154|cit154","unstructured":"Effect of cannabinoids on spasticity and neuropathic pain in spinal cord injured persons clinicaltrials.gov\/ct2\/show\/NCT01222468?term=NCT01222468&rank=1"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0155|cit155","unstructured":"Trial of dronabinol and vaporized cannabis in chronic low back pain https:\/\/clinicaltrials.gov\/study\/NCT02460692 2015 Last update posted 2023-09-28"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.clinthera.2017.01.016","article-title":"Effects on Spasticity and Neuropathic Pain of an Oral Formulation of \u03949-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis","volume":"40","author":"Amerongen","year":"2018","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jama.2014.8166","article-title":"Association between analytic strategy and estimates of treatment outcomes in meta-analyses","volume":"312","author":"Dechartres","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD012182.pub3-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study","volume":"341","author":"N\u00fcesch","year":"2010","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"10","key":"10.1002\/14651858.CD012182.pub3-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"e25491","DOI":"10.1371\/journal.pone.0025491","article-title":"The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis: a simulation study","volume":"6","author":"Thorlund","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1002\/14651858.CD012182.pub3-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ijcard.2012.11.048","article-title":"Random error in cardiovascular meta-analyses: how common are false positive and false negative results?","volume":"168","author":"AlBalawi","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012182.pub3-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"e59202","DOI":"10.1371\/journal.pone.0059202","article-title":"The impact of study size on meta-analyses: examination of underpowered studies in Cochrane Reviews","volume":"8","author":"Turner","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1002\/14651858.CD012182.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0165|cit165","unstructured":"Guideline on the clinical development of medicinal products intended for the treatment of pain (15 December 2016) https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-development-medicinal-products-intended-treatment-pain-first-version_en.pdf"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jpain.2015.07.014","article-title":"Cannabis for the management of pain: assessment of safety study (COMPASS)","volume":"16","author":"Ware","year":"2015","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/j.pain.0000000000000753","article-title":"Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles","volume":"158","author":"Baron","year":"2017","journal-title":"Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/0269215513514231","article-title":"How to measure pain in neurological conditions? A systematic review of psychometric properties and clinical utility of measurement tools","volume":"28","author":"Tyson","year":"2014","journal-title":"Clinical Rehabilitation"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0169|cit169","first-page":"43","article-title":"Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect","volume":"116","author":"Mintzes","year":"2015","journal-title":"British Medical Bulletin"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0170|cit170","first-page":"1134","article-title":"Pharmacoepidemiological research with large health databases","volume":"51","author":"Andersohn","year":"2008","journal-title":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpain.2023.10.009","article-title":"Cannabidiol (CBD) products for pain: ineffective, expensive, and with potential harms","volume":"25","author":"Moore","year":"2024","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1590\/0004-282X20200166","article-title":"Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology","volume":"14","author":"Oliveira","year":"2020","journal-title":"Arquivos de Neuro-Psiquiatria"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s43856-022-00156-x","article-title":"Patient involvement in clinical trials","volume":"2","author":"Gei\u00dfler","year":"2022","journal-title":"Communications Medicine (London)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/AJP.0b013e3182321ad8","article-title":"Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review","volume":"28","author":"H\u00e4user","year":"2012","journal-title":"Clinical Journal of Pain"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1526-4637.2012.01340.x","article-title":"Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis","volume":"13","author":"Cepeda","year":"2012","journal-title":"Pain Medicine (Malden, Mass.)"},{"key":"10.1002\/14651858.CD012182.pub3-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1097\/j.pain.0000000000000492","article-title":"Neuropathic pain: an updated grading system for research and clinical practice","volume":"157","author":"Finnerup","year":"2016","journal-title":"Pain"},{"issue":"5","key":"10.1002\/14651858.CD012182.pub3-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012182","article-title":"Cannabinoids for chronic neuropathic pain","author":"M\u00fccke","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:47:41Z","timestamp":1793004461000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012182.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":177,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012182.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]}}}